12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
phoma. The patients with metabolic syndrome have a twice higher risk
to develop non-Hodgkin lymphoma. The risk increases with the number
of components of the metabolic syndrome they present.
1424
THE CURRENT OPINION OF THE PATIENTS FROM SOUTHERN TRANSYLVANIA
REGARDING THE BLOOD TRANSFUSION
R. Mihaila, 1 R. Mihaila, 2 E.C. Rezi, 3 L. Tiurean, 3 M. Deac, 2 A. Fraticiu, 3
A. Catana, 3 D. Dascalu, 3 C. Bidlo, 3 C. Dinca, 3 R. Barbu3 1 Public Health Authority, SIBIU, Romania; 2 Lucian Blaga University, SIBIU,
Romania; 3 Departmental Clinical Hospital, SIBIU, Romania
Background. Together with Romania’s attendance to the European
Union, it is stipulated that blood transfusion should become honorific
and this can have implications on the act of transfusion. Aim. We established
this study in order to see the patients’ attitude concerning the
blood donation and the blood transfusion. Methods. We have performed
a transversal study in which we have included all the 112 patients from
the medical departments of the Clinical County Hospital from Sibiu
during 19-23.02.2007, who have agreed to answer at a questionnaire
with 10 questions regarding the blood transfusion. Each question had 3
variants of answer. We have analyzed the rates of the answers, their significations
and we have drawn useful conclusions for medical practice.
Results. Even though the majority of the questioned patients (96%) agree
that a patient can be transfused if this act can save his life or ameliorate
his evolution, 66% of them did not donate blood ever. 97% would
donate blood for a family member, but 11% would not donate for an
unknown person. 38% from them consider that the blood donation
must be compensated with money. Most of them (92%) agree that all
the patients who need transfusions to get them, not only those who do
not have cancer. 39% of the questioned people do not know if the blood
transfusion can prolong the life of a patient with acute leukemia. A part
of them (16%) do not know if viruses or bacteria can be transmitted
through a blood transfusion; 37% do not know and 24% are not sure
which are the risks of a blood transfusion. 34% from the questioned
patients declare that they would not accept the blood transfusion from
an anonymous donator, knowing that it can be risky, 56% would accept
it and 10% do not know. Conclusions. The majority of the questioned
patients agree that all those who need blood to be transfused. Only a
third of them donated blood at least once. More then a third would still
like that the blood donation to be compensated with money. Many of
them are insufficiently informed about the risks and benefits of the
blood transfusion, this thing been well reflected in their attitude on
receiving blood from unknown donators and donating blood to
unknown people.
1425
AUTOTRANSPLANT AFTER PURGING IN VIVO IN PATIENTS WITH LYMPHOPROLIFERATIVE
DISEASE A POOR PROGNOSYS
V. Mettivier, L. Pezzullo, O. Finizio, S. Rocco, L. Bene, M.G. Ferrara
A.O.R.N. „A,Cardarelli„, NAPLES, Italy
Autologous stem cell transplantation is a efficacy therapy for limphoproliferative
disease. However a concern with the procedure is the
potential of malignant cells to reinfuse with stem-cell graft. In the past
five year, investigators have used rituximab to purge malignant cells in
vivo without any manipulation in vitro. From April 2003 to December
2006 we have treated with Autologous stem cell transplantation, purged
in vivo with monoclonal antibodies, 20 patients (5 F; M 15 median age:
57 years) with limphoproliferative diseases to poor prognosis (3 Burkitt
lymphoma; 4 mantle cells; 3 CLL; 1 NHL- peripheral T cells; 2 follicular
and 7 large cells) and we have evaluated the results and the feasibility.
In all patients, the purged in vivo, has been effected administering a dose
of monoclonal antibodies (anti CD20 in B-NHL and anti CD52 in CLL
and T-NHL) before the harvest and after the infusion of the stem-cells.
To the transplantation 6 patients were in CR (3 Burkitt lymphoma; 2
large cells and 1 mantle cells) 10 in PR (1 CLL; 3 mantle cells; 2 follicular
and 4 large cells lymphoma) and 4 in resistant disease (2 CLL ; 1 large
cells and 1 NHL peripheral T cells) All patients have harvest (median
CD34:4 ×106 /Kg) and median minimal residual disease in the harvest has
been < to 2%. All the patients have been conditioned with BEAM and
the graft are documented in 18/20 patients (2 patient is dead to the day
+4 and +10 for gastric haemorrhage and septic shock respectively) with
neutrophils> 1000 in media to day + 14 (range 10-19 days). After transplantation
17/18 patients were in CR, a day +60 the MMR in bone marrow
was